Stockholm

• A Randomized Open Label Trial Exploring the Soluble and Imaging Biomarker Dynamic Responses to Tolebrutinib Compared to Rituximab Treatment … Pending
  2025-523892-50-00 5 Multiple Sclerosis
• A Phase 3 Study of Orelabrutinib in Non-active Secondary Progressive Multiple Sclerosis Pending
  2025-524322-18-00 5 Non-active Secondary Progressive Multiple Sclerosis (SPMS)
• Morphine for resting breathlessness in severe illness and palliative care (MORE-B): a randomized clinical trial Pending
  2026-525838-32-00 6 Serious, chronic, life-limiting disease
• Montelukast as disease modifying treatment in mild-moderate Parkinson’s disease, an open-label, phase II extension trial (MONTPARK_OLE) Pending
  2026-525906-37-00 5 Parkinson's Disease
• Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year Recruiting
  2025-521590-13-00 5 2026-05-28 Moderately to Severely Active Crohn’s Disease
• A Study of the Efficacy and Safety of Danicamtiv in Participants with Symptomatic Genetic and Familial Dilated Cardiomyopathy. Recruiting
  2025-522553-19-00 10 2026-02-25 Symptomatic genetic and familial dilated cardiomyopathy.
• A Phase III Randomised, Open Label Trial of an Intradermal or Subcutaneous booster dose of MVA-BN Vaccine to Investigate MPXV Immunogenicity … Recruiting
  2024-518007-22-00 5 2025-12-05 Prevention of monkeypox (mpox) infection
• Long-term study to assess the safety and tolerability of adjunctive NBI-1065845 in adults with Major Depressive Disorder (MDD) Recruiting
  2024-519423-24-00 5 2025-10-07 Major Depressive Disorder
• A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder Recruiting
  2024-520195-94-00 5 2025-09-25 BP-I mania or mania with mixed features
• A Phase 3 Open-label Extension Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder Recruiting
  2024-520259-26-00 5 2025-09-25 Mania or Mania with Mixed Features in Bipolar-I Disorder
• Clinical study of ruxolitinib and venetoclax for children with relapsed or refractory leukemia or lymphoma with mutations in the IL-7R/JAK-S … Recruiting
  2022-501867-42-01 9 2025-09-08 Acute Lymphoblastic Leukemia, in Relapse Lymphoblastic Lymphoma (Precu
• Medical-scientific study of dasatinib and venetoclax for children with relapsed or refractory leukemia or lymphoma with a mutation in the MA … Recruiting
  2022-501866-22-00 9 2025-08-26 Acute Lymphoblastic Leukemia, in Relapse Lymphoblastic Lymphoma (Precu
• Empirical Meropenem versus Piperacillin/Tazobactam for Adult Patients with Sepsis (EMPRESS) Recruiting
  2023-509703-33-00 6 2025-06-26 Septic Shock
• The Intensive Care Platform Trial (INCEPT) Recruiting
  2024-516208-41-00 6 2025-06-26 Acute critical illness requiring intensive care unit admission.
• Long-term safety and efficacy study of riliprubart in participants with CIDP Recruiting
  2024-517032-22-00 5 2025-06-10 Immune system diseases.
• A clinical trial to learn about the effects of VHB937 in people with amyotrophic lateral sclerosis (ALS) Recruiting
  2024-512536-29-00 4 2025-02-28 Amyotrophic Lateral Sclerosis (ALS)
• A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients with … Recruiting
  2023-510369-92-00 4 2025-01-28 Mixed Dyslipidemia
• A RANDOMIZED, OPEN-LABEL PHASE 3 STUDY IN PATIENTS WITH PREVIOUSLY TREATED UNRESECTABLE OR METASTATIC NRAS MUTANT CUTANEOUS MELANOMA COMPARI … Recruiting
  2024-511404-17-00 5 2024-10-07 Unresectable or metastatic NRAS mutant cutaneous melanoma
• A Phase 2 Clinical Trial to Investigate Safety, Tolerability and Efficacy of TransCon CNP, Weekly Subcutaneous Injections, Compared with Pla … Recruiting
  2023-506091-27-00 4 2024-09-19 Achondroplasia in Children and Adolescents
• A Phase 2 study of DNTH103 in patients with Generalized Myasthenia Gravis Recruiting
  2024-512865-15-00 4 2024-09-03 Generalized Myasthenia Gravis
• AZD5305 vs Placebo in Men with Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents. Recruiting
  2023-504214-30-00 5 2024-06-27 Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
• Crohn's Disease: Pharmacokinetics, Efficacy, and Safety of Risankizumab in Pediatric Subjects with Moderately to Severely Active Crohn's Dis … Recruiting
  2022-502050-14-00 5 2024-06-04 Crohn's disease
• Long-term Extension Study to Assess Adverse Events and Tolerability of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Ag … Recruiting
  2022-501099-24-00 5 2023-12-22 Migraine
• A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) … Recruiting
  2022-501100-94-00 5 2023-11-08 Episodic Migraine

Showing 25–48 of 243 trials